In one study, advanced prostate cancer patients had a higher frequency of a variant on the 3’UTR of CDKN1A [60] and the gene has received attention as a potential therapeutic target for prostate cancer [61]. This evidence concerns the gene CDKN1A and prostate carcinoma.